Equities research analysts expect Imperva Inc (NYSE:IMPV) to post $0.24 earnings per share for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Imperva’s earnings. The highest EPS estimate is $0.26 and the lowest is $0.23. Imperva posted earnings per share of $0.08 in the same quarter last year, which indicates a positive year-over-year growth rate of 200%. The company is expected to report its next earnings report on Thursday, November 2nd.

On average, analysts expect that Imperva will report full year earnings of $0.81 per share for the current financial year, with EPS estimates ranging from $0.79 to $0.83. For the next financial year, analysts forecast that the firm will report earnings of $0.94 per share, with EPS estimates ranging from $0.73 to $1.04. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Imperva.

Imperva (NYSE:IMPV) last posted its quarterly earnings data on Thursday, July 27th. The software maker reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.15). Imperva had a negative return on equity of 5.00% and a negative net margin of 4.69%. The firm had revenue of $74.44 million for the quarter, compared to analysts’ expectations of $74.30 million. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. The company’s revenue for the quarter was up 28.6% on a year-over-year basis.

Several equities research analysts have weighed in on the stock. UBS AG assumed coverage on shares of Imperva in a report on Tuesday, June 6th. They issued a “positive” rating and a $60.00 target price on the stock. Susquehanna Bancshares Inc assumed coverage on shares of Imperva in a report on Wednesday, June 7th. They issued a “positive” rating and a $60.00 target price on the stock. BidaskClub lowered shares of Imperva from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 5th. ValuEngine lowered shares of Imperva from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Finally, Stephens reiterated an “overweight” rating and issued a $61.00 target price (up from $53.00) on shares of Imperva in a report on Thursday, July 13th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $52.97.

Imperva (IMPV) traded down 0.23% during trading on Thursday, reaching $43.30. 411,989 shares of the company’s stock traded hands. Imperva has a 12 month low of $34.40 and a 12 month high of $57.24. The firm’s 50 day moving average is $44.67 and its 200 day moving average is $45.51. The company’s market cap is $1.46 billion.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/14/0-24-eps-expected-for-imperva-inc-impv-this-quarter.html.

In related news, Director Anthony J. Bettencourt sold 99,598 shares of the firm’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $43.59, for a total value of $4,341,476.82. Following the completion of the transaction, the director now owns 99,598 shares of the company’s stock, valued at $4,341,476.82. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.20% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. grew its position in shares of Imperva by 18.7% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,940 shares of the software maker’s stock valued at $141,000 after acquiring an additional 464 shares during the period. California State Teachers Retirement System grew its position in shares of Imperva by 5.1% in the 2nd quarter. California State Teachers Retirement System now owns 59,306 shares of the software maker’s stock valued at $2,838,000 after acquiring an additional 2,872 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Imperva by 15.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 25,684 shares of the software maker’s stock valued at $1,229,000 after acquiring an additional 3,348 shares during the period. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Imperva by 26.2% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,177 shares of the software maker’s stock valued at $201,000 after acquiring an additional 866 shares during the period. Finally, Cubist Systematic Strategies LLC grew its position in shares of Imperva by 34.8% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 12,969 shares of the software maker’s stock valued at $621,000 after acquiring an additional 3,349 shares during the period. 92.72% of the stock is owned by institutional investors.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Get a free copy of the Zacks research report on Imperva (IMPV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.